Skip to Content

Press Releases

Intec Pharma Reports First Half 2016 Financial Results

September 1, 2016 at 6:00 AM EDT

Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, reports financial results for the three and six months ended June 30, 2016.

Highlights of the first six months of 2016 and recent weeks include:

  • Initiated patient enrollment in the pivotal Phase III clinical trial for the Accordion Pill Carbidopa/Levodopa, or AP-CDLD, for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients;
  • Initiated a clinical development program for AP-CBD/THC, an Accordion Pill platform with the two primary cannabinoids contained in Cannabis sativa for the treatment of various indications, including pain management;
  • Received approval for a $5.2 million grant from the Israeli National Authority for Technological Innovation (NATI) (formerly known as the Israel Office of the Chief Scientist) in connection with the Company’s 2016 research and development programs;
  • Nominated Dr. John W. Kozarich, Chairman of the Board of Ligand Pharmaceuticals (Nasdaq: LGND), to act as Intec Pharma’s Chairman of the Board of Directors;
  • Completed a Phase I clinical trial of the Company’s Accordion Pill technology being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug (NSAID) induced ulcers, for which the pharmacokinetics (PK) results were within the well-defined safety levels of the drug, and enable the Company to proceed with further development of this indication;
  • Expanded intellectual property for AP-CDLD in South Korea after being granted a South Korean patent by the Korean Intellectual Property Office; and
  • Appointed Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs.

Management Commentary

“The first half of 2016 was a very productive and exciting time for Intec Pharma as we achieved a number of important milestones that advanced our strategy to utilize our innovative Accordion Pill platform to bring innovative new therapies to patients in need,” said Zeev Weiss, Chief Executive Officer of Intec Pharma. “Importantly, we initiated patient enrollment in the pivotal Phase III clinical trial of AP-CDLD for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients.”

“We were very pleased to introduce our new clinical development program with our Accordion Pill platform to safely and effectively deliver two primary cannabinoids for the treatment of various indications including pain management. Current methods of use and treatment with cannabis and cannabinoids are short-acting, which leads to a variety of therapeutic obstacles and gives rise to the need to improve the efficacy and safety of cannabinoids as therapeutics. We believe our Accordion Pill offers a unique opportunity to provide a long-acting oral therapy of THC and CBD for various indications. We look forward to initiating a Phase I study in the first quarter of 2017,” added Mr. Weiss.

Financial Highlights for the Three and Six Months Ended June 30, 2016

Research and Development Expenses, net for the three months ended June 30, 2016 amounted to approximately $1.3 million, compared with approximately $449,000 for the three months ended June 30, 2015. Research and Development Expenses, net for the six months ended June 30, 2016 amounted to approximately $5.4 million, compared with approximately $1.8 million for the six months ended June 30, 2015. The increase in both periods resulted primarily from an increase in expenses of our Phase III clinical trial for our lead product, AP-CDLD for the treatment of Parkinson’s disease symptoms, payroll and related expenses, which were partially offset by an increase in participation in research and development expenses from the NATI.

General and Administrative Expenses for the three months ended June 30, 2016 were approximately $756,000, compared with approximately $530,000 for the three months ended June 30, 2015. General and Administrative Expenses for the six months ended June 30, 2016 were approximately $1.5 million, compared with approximately $1.1 million for the six months ended June 30, 2015. The increase in both periods were primarily due to an increase in professional services and other expenses associated with being a public company in the United States since August 2015.

Net Loss for the three months ended June 30, 2016 was approximately $2.0 million or $0.18 per share, based on 11.4 million basic and diluted shares, compared with a net loss of approximately $883,000 or $0.16 per share, based on 5.5 million basic and diluted shares, for the three months ended June 30, 2015. Net Loss for the six months ended June 30, 2016, was approximately $6.4 million or $0.56 per share, based on 11.4 million basic and diluted shares, compared with a net loss of approximately $2.8 million or $0.51 per share, based on 5.6 million basic and diluted shares, for the six months ended June 30, 2015.

Net cash used in operating activities for the six months ended June 30, 2016 was approximately $9.4 million compared with net cash used in operating activities of approximately $3.4 million for the six months ended June 30, 2015. This increase primarily resulted from an increase in our loss and comprehensive loss of approximately $3.7 million and an increase in changes in operating asset and liability items of approximately $2.2 million.

Net cash provided by investment activities for the six months ended June 30, 2016 was approximately $74,000, compared with net cash used in investment activities of approximately $865,000 for the six months ended June 30, 2015. The change primarily resulted from a decrease in the purchase of property and equipment in the amount of approximately $778,000.

Cash, cash equivalents, short term bank deposits and financial assets at fair value as of June 30, 2016 were approximately $21.4 million as compared with approximately $30.7 million as of December 31, 2015. The decrease was a result of the ongoing operations, mainly related to research and development activities.

Advances to suppliers and other receivables as of June 30, 2016 were approximately $5.5 million and consisted primarily of advances to suppliers related to the pivotal Phase III clinical trial with AP-CDLD in the amount of $2.3 million and grants receivable from NATI in the amount of $2.9 million.

During the balance of 2016 the Company will continue to invest in advancing its clinical development pipeline, primarily in its pivotal Phase III clinical trial of AP-CDLD and in its newly launched AP-CBD/THC for the development of therapies utilizing two primary cannabinoids contained in Cannabis sativa for the treatment of various indications, including pain management.

About Intec Pharma Ltd.

Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, which is being developed for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, Accordion Pill Zaleplon, or AP-ZP, which is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance, and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, and include the following: the company’s ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company’s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

 
INTEC PHARMA LTD.

CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

             
     

December 31,
2015

   

June 30,
2016

     

(Audited)

   

(Unaudited)

     

U.S. dollars in thousands

A s s e t s            
CURRENT ASSETS:            
Cash and cash equivalents     23,649       14,454  
Short-term bank deposits     5,000       5,000  
Financial assets at fair value through profit or loss     2,024       1,925  
Restricted bank deposits     62       62  
Advances to suppliers and other receivables     2,361       5,479  

 

    33,096       26,920  

NON-CURRENT ASSETS -

           
Property and equipment     4,076       3,775  
TOTAL ASSETS     37,172       30,695  
             
Liabilities and equity            
CURRENT LIABILITIES -            
Accounts payable and accruals:            
Trade     614       305  
Other     701       1,044  
      1,315       1,349  
NON-CURRENT LIABILITIES -            
Derivative financial instruments     327       110  
COMMITMENTS AND CONTINGENT LIABILITIES            
TOTAL LIABILITIES     1,642       1,459  
             
EQUITY:            
Ordinary shares     727       727  
Share premium     84,980       84,980  
Currency translation differences     (378 )     (378 )
Accumulated deficit     (49,799 )     (56,093 )
TOTAL EQUITY     35,530       29,236  
TOTAL LIABILITIES AND EQUITY     37,172       30,695  
                 
 
INTEC PHARMA LTD.

CONDENSED INTERIM STATEMENT OF COMPREHENSIVE LOSS

             
     

Three months ended
June 30

   

Six months ended
June 30

     

2015

   

2016

   

2015

   

2016

     

(Unaudited)

     

U.S. dollars in thousands

                         
RESEARCH AND DEVELOPMENT EXPENSES     (1,277 )     (3,524 )     (2,695 )     (7,664 )
LESS - PARTICIPATION IN RESEARCH AND DEVELOPMENT EXPENSES     828       2,241       862       2,241  
RESEARCH AND DEVELOPMENT EXPENSES, net     (449 )     (1,283 )     (1,833 )     (5,423 )
GENERAL AND ADMINISTRATIVE EXPENSES     (530 )     (756 )     (1,141 )     (1,515 )
OTHER GAINS (LOSSES), net     (27 )     (34 )     (4 )     30  
OPERATING LOSS     (1,006 )     (2,073 )     (2,978 )     (6,908 )
FINANCIAL INCOME     211       97       362       473  
FINANCIAL EXPENSES     (88 )     (35 )     (173 )     (9 )
NET LOSS     (883 )     (2,011 )     (2,789 )     (6,444 )
OTHER COMPREHENSIVE LOSS -                        
CURRENCY TRANSLATION DIFFERENCES     492       -       292       -  
LOSS AND COMPREHENSIVE LOSS     (391 )     (2,011 )     (2,497 )     (6,444 )
                         
     

$

BASIC AND DILUTED LOSS PER ORDINARY SHARE

   

(0.16

)

   

(0.18

)

   

(0.51

)

   

(0.56

)

                                 
 
INTEC PHARMA LTD.

CONDENSED INTERIM STATEMENTS OF CASH FLOWS

       
     

Six months ended
June 30

     

2015

   

2016

     

(Unaudited)

     

U.S. dollars
in thousands

CASH FLOWS FROM OPERATING ACTIVITIES:            
Comprehensive loss     (2,789 )     (6,444 )
Adjustments to reconcile loss and comprehensive loss to net cash used in operating activities (see appendix A)     (602 )     (2,918 )
Net cash used in operating activities     (3,391 )     (9,362 )
CASH FLOWS FROM INVESTING ACTIVITIES:            
Purchase of property and equipment     (833 )     (55 )
Proceeds from disposal (acquisition) of financial assets at fair value through profit or loss, net     (45 )     129  
Changes in restricted bank deposits, net     13        
Net cash provided by (used in) investing activities     (865 )     74  
CASH FLOWS FROM FINANCING ACTIVITIES:            
Exercise of warrants (series 7)     1,844       -  
Deferred issuance expenses     (261 )     -  
Net cash provided by financing activities     1,583       -  
DECREASE IN CASH AND CASH EQUIVALENTS     (2,673 )     (9,288 )
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD     5,731       23,649  
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS     (18 )     93  
CASH AND CASH EQUIVALENTS - END OF PERIOD     3,040       14,454  
                 
 
INTEC PHARMA LTD.

CONDENSED INTERIM STATEMENTS OF CASH FLOWS

             
     

Six months ended
June 30

     

2015

   

2016

     

(Unaudited)

     

U.S. dollars
in thousands

APPENDIX A:

           
             
Adjustments to reconcile loss and comprehensive loss to net cash used in operating activities:            
             
Income and expenses not involving cash flows:            
Depreciation     252       356  
Changes in the fair value of derivative financial instruments     (241 )     (217 )
Exchange differences on cash and cash equivalents     123       (93 )
Losses (gains) on financial assets at fair value through profit or loss     4       (30 )
Share-based compensation to employees and service providers     187       150  
      325       166  
Changes in operating asset and liability items:            
Increase in advances to suppliers and other receivables     (1,331 )     (3,118 )
Increase in accounts payable and accruals     404       34  
      (927 )     (3,084 )
      (602 )     (2,918 )
APPENDIX B:            
             

Information regarding investment and financing activities not involving cash flows:

           
Liability with respect to property purchase     147        
Deferred issuance expenses     400        

Supplementary information to the statement of cash flows -

           
Interest received     15       109  

 

Intec Pharma
Zeev Weiss, +972-(2)586-4657
Chief Executive Officer
zeev@intecpharma.com
or
LHA
Anne Marie Fields, 212-838-3777
Senior Vice President
afields@lhai.com

Copyright Business Wire 2016

 

Source: Business Wire (September 1, 2016 - 6:00 AM EDT)